Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model

Laura G. Remsen, Carol Marquez, Raymond Garcia, Lori A. Thrun, Edward Neuwelt

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: The objective of this study was to evaluate the efficacy of sequencing radiation therapy (RT) and antibody targeted chemotherapy (BR96-DOX) in nude rats bearing human lung cancer (B.5 LX-1) intracerebral (i.c.) xenografts. Methods and Materials: Our approach was to administer RT using 20 Gy single-fraction cranial irradiation either before, concurrent with, or after BR96-DOX treatment via osmotic blood-brain barrier disruption to enhance immunoconjugate delivery. All rats were inoculated with i.c. B.5 LX-1 tumors and were randomly assigned to treatment groups. Results: BR96-DOX alone on Day 6 or Day 12 significantly increased survival compared to negative control rats receiving no treatment (25.9 ± 2.1 and 23.3 ± 2.5 days vs. 14.8 ± 1.9 days, p <0.05). Rats that received chemotherapy before radiation (34.0 ± 2.0 days) lived the longest compared to the other sequences (RT prior, 29.5 ± 1.9; RT concurrent, 27.1 ± 2.1). Histopathology of 39 rat brains did not reveal any neuropathology. Conclusions: Enhanced delivery of immunoconjugates is more effective in combination with RT for the treatment of experimental metastatic brain tumors. Moreover, BR96-DOX administration prior to RT significantly increased survival compared to those receiving RT and chemotherapy concurrently (p <0.05).

Original languageEnglish (US)
Pages (from-to)1045-1049
Number of pages5
JournalInternational Journal of Radiation Oncology Biology Physics
Volume51
Issue number4
DOIs
StatePublished - Nov 15 2001

Fingerprint

rodents
sequencing
chemotherapy
antibodies
Heterografts
Brain Neoplasms
lungs
brain
radiation therapy
Rodentia
Lung Neoplasms
delivery
Radiotherapy
cancer
rats
Drug Therapy
Antibodies
Brain
Immunoconjugates
tumors

Keywords

  • Blood-brain barrier
  • Monoclonal antibody
  • Radiotherapy
  • Tumor model

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model. / Remsen, Laura G.; Marquez, Carol; Garcia, Raymond; Thrun, Lori A.; Neuwelt, Edward.

In: International Journal of Radiation Oncology Biology Physics, Vol. 51, No. 4, 15.11.2001, p. 1045-1049.

Research output: Contribution to journalArticle

@article{1ec103a831a247d6a9b41e709b9c73a7,
title = "Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model",
abstract = "Purpose: The objective of this study was to evaluate the efficacy of sequencing radiation therapy (RT) and antibody targeted chemotherapy (BR96-DOX) in nude rats bearing human lung cancer (B.5 LX-1) intracerebral (i.c.) xenografts. Methods and Materials: Our approach was to administer RT using 20 Gy single-fraction cranial irradiation either before, concurrent with, or after BR96-DOX treatment via osmotic blood-brain barrier disruption to enhance immunoconjugate delivery. All rats were inoculated with i.c. B.5 LX-1 tumors and were randomly assigned to treatment groups. Results: BR96-DOX alone on Day 6 or Day 12 significantly increased survival compared to negative control rats receiving no treatment (25.9 ± 2.1 and 23.3 ± 2.5 days vs. 14.8 ± 1.9 days, p <0.05). Rats that received chemotherapy before radiation (34.0 ± 2.0 days) lived the longest compared to the other sequences (RT prior, 29.5 ± 1.9; RT concurrent, 27.1 ± 2.1). Histopathology of 39 rat brains did not reveal any neuropathology. Conclusions: Enhanced delivery of immunoconjugates is more effective in combination with RT for the treatment of experimental metastatic brain tumors. Moreover, BR96-DOX administration prior to RT significantly increased survival compared to those receiving RT and chemotherapy concurrently (p <0.05).",
keywords = "Blood-brain barrier, Monoclonal antibody, Radiotherapy, Tumor model",
author = "Remsen, {Laura G.} and Carol Marquez and Raymond Garcia and Thrun, {Lori A.} and Edward Neuwelt",
year = "2001",
month = "11",
day = "15",
doi = "10.1016/S0360-3016(01)01743-6",
language = "English (US)",
volume = "51",
pages = "1045--1049",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Efficacy after sequencing of brain radiotherapy and enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model

AU - Remsen, Laura G.

AU - Marquez, Carol

AU - Garcia, Raymond

AU - Thrun, Lori A.

AU - Neuwelt, Edward

PY - 2001/11/15

Y1 - 2001/11/15

N2 - Purpose: The objective of this study was to evaluate the efficacy of sequencing radiation therapy (RT) and antibody targeted chemotherapy (BR96-DOX) in nude rats bearing human lung cancer (B.5 LX-1) intracerebral (i.c.) xenografts. Methods and Materials: Our approach was to administer RT using 20 Gy single-fraction cranial irradiation either before, concurrent with, or after BR96-DOX treatment via osmotic blood-brain barrier disruption to enhance immunoconjugate delivery. All rats were inoculated with i.c. B.5 LX-1 tumors and were randomly assigned to treatment groups. Results: BR96-DOX alone on Day 6 or Day 12 significantly increased survival compared to negative control rats receiving no treatment (25.9 ± 2.1 and 23.3 ± 2.5 days vs. 14.8 ± 1.9 days, p <0.05). Rats that received chemotherapy before radiation (34.0 ± 2.0 days) lived the longest compared to the other sequences (RT prior, 29.5 ± 1.9; RT concurrent, 27.1 ± 2.1). Histopathology of 39 rat brains did not reveal any neuropathology. Conclusions: Enhanced delivery of immunoconjugates is more effective in combination with RT for the treatment of experimental metastatic brain tumors. Moreover, BR96-DOX administration prior to RT significantly increased survival compared to those receiving RT and chemotherapy concurrently (p <0.05).

AB - Purpose: The objective of this study was to evaluate the efficacy of sequencing radiation therapy (RT) and antibody targeted chemotherapy (BR96-DOX) in nude rats bearing human lung cancer (B.5 LX-1) intracerebral (i.c.) xenografts. Methods and Materials: Our approach was to administer RT using 20 Gy single-fraction cranial irradiation either before, concurrent with, or after BR96-DOX treatment via osmotic blood-brain barrier disruption to enhance immunoconjugate delivery. All rats were inoculated with i.c. B.5 LX-1 tumors and were randomly assigned to treatment groups. Results: BR96-DOX alone on Day 6 or Day 12 significantly increased survival compared to negative control rats receiving no treatment (25.9 ± 2.1 and 23.3 ± 2.5 days vs. 14.8 ± 1.9 days, p <0.05). Rats that received chemotherapy before radiation (34.0 ± 2.0 days) lived the longest compared to the other sequences (RT prior, 29.5 ± 1.9; RT concurrent, 27.1 ± 2.1). Histopathology of 39 rat brains did not reveal any neuropathology. Conclusions: Enhanced delivery of immunoconjugates is more effective in combination with RT for the treatment of experimental metastatic brain tumors. Moreover, BR96-DOX administration prior to RT significantly increased survival compared to those receiving RT and chemotherapy concurrently (p <0.05).

KW - Blood-brain barrier

KW - Monoclonal antibody

KW - Radiotherapy

KW - Tumor model

UR - http://www.scopus.com/inward/record.url?scp=0035889378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035889378&partnerID=8YFLogxK

U2 - 10.1016/S0360-3016(01)01743-6

DO - 10.1016/S0360-3016(01)01743-6

M3 - Article

VL - 51

SP - 1045

EP - 1049

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 4

ER -